Previous close | 286.30 |
Open | 287.84 |
Bid | 284.33 x 100 |
Ask | 284.60 x 100 |
Day's range | 284.21 - 288.54 |
52-week range | 211.71 - 329.72 |
Volume | |
Avg. volume | 3,041,290 |
Market cap | 152.372B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | 22.78 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.00 (3.17%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024.
Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday, March 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.